ly3841136
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Mar 30, 2022 (NCT05295940)
Timeline
Indications
Mechanism of action
Amylin receptor AMY1, CALCR/RAMP1 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068462 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282600 | Phase 3 | Dec 15, 2025 | Eli Lilly |
| NCT07215559 | Phase 2 | Oct 16, 2025 | Eli Lilly |
| NCT06916091 | Phase 1 | Apr 21, 2025 | Eli Lilly |
| NCT06916065 | Phase 1 | Apr 9, 2025 | Eli Lilly |
| NCT06603571 | Phase 2 | Sep 20, 2024 | Eli Lilly |
| NCT06297616 | Phase 1 | Apr 15, 2024 | Eli Lilly |
| NCT06345066 | Phase 1 | Apr 3, 2024 | Eli Lilly |
| NCT06230523 | Phase 2 | Feb 5, 2024 | Eli Lilly |
| NCT05295940 | Phase 1 | Mar 30, 2022 | Eli Lilly |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 9 | 9 | 3 | 2022 |
1 organizations
Page 1 / 1